Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Goldstone

Showing results (301-310 of 311) with videos related to

Pageof 32
Sort By:
British Journal of Haematology|March 29, 2020
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trialChezi Ganzel, Xin V Wang, Jacob M Rowe, et al.
Blood|October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJosé A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
Blood|December 16, 2006
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman, Christine J Harrison, Georgina A N Buck, et al.
Cytotherapy|August 13, 2002
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Blood|September 26, 2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
British Journal of Haematology|May 19, 2004
Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemiaChristine J Harrison, Anthony V Moorman, Zoë J Broadfield, et al.
The Lancet. Haematology|March 31, 2022
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trialDavid I Marks, Amy A Kirkwood, Clare J Rowntree, et al.
Blood Cancer Journal|July 5, 2024
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 yearsPhilipp Berning, Mathilde Fekom, Maud Ngoya, et al.
Leukemia|December 25, 2009
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008M Brüggemann, A Schrauder, T Raff, et al.
Nature|May 23, 2007
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancersRichard S Maser, Bhudipa Choudhury, Peter J Campbell, et al.
Pageof 32

Showing results (301-310 of 311) with videos related to

Sort By:
Pageof 32
British Journal of Haematology|March 29, 2020
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trialChezi Ganzel, Xin V Wang, Jacob M Rowe, et al.
Blood|October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJosé A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
Blood|December 16, 2006
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman, Christine J Harrison, Georgina A N Buck, et al.
Cytotherapy|August 13, 2002
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Blood|September 26, 2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
British Journal of Haematology|May 19, 2004
Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemiaChristine J Harrison, Anthony V Moorman, Zoë J Broadfield, et al.
The Lancet. Haematology|March 31, 2022
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trialDavid I Marks, Amy A Kirkwood, Clare J Rowntree, et al.
Blood Cancer Journal|July 5, 2024
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 yearsPhilipp Berning, Mathilde Fekom, Maud Ngoya, et al.
Leukemia|December 25, 2009
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008M Brüggemann, A Schrauder, T Raff, et al.
Nature|May 23, 2007
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancersRichard S Maser, Bhudipa Choudhury, Peter J Campbell, et al.
Pageof 32